-
PROVIDERS
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
LIFE SCIENCES
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
Content
-
WebinarsAdvancing IO therapeutics: The convergence of novel biomarkers and combination strategies
Explore the latest in immuno-oncology (IO), where emerging therapies are reshaping the landscape of cancer treatment. This webinar will focus on the role of novel biomarkers and combination treatment strategies in understanding and enhancing the immune system's response to cancer. -
White papersThe future of immuno-oncology research: Challenges, innovations, and the role of data-driven solutions
This white paper offers an in-depth look at immuno-oncology (IO) research, emphasizing how data-driven research propels therapy development and enhances treatment efficacy. -
Case StudiesMaximizing precision in pathology: the Critical Path approach
Enhancing tissue utilization, reducing turnaround time, and optimizing testing pathways with AI-driven insights. -
Case StudiesIdentifying MSI-high in prostate cancer using AI-powered digital pathology
How AI algorithms and digital pathology can streamline the diagnosis and treatment of prostate cancer patients. -
Webinars
Precision outcomes research: Shaping the future of oncology biopharma with real-world evidence
Delve into the evolving landscape of outcomes research with a focus on real-world evidence (RWE) and advanced analytics. -
Case StudiesAn algorithmic approach to close care gaps for patients that may benefit from confirmatory IHC HER2 testing
In partnership with a global pharmaceutical company, Tempus Next deployed a HER2 predictive algorithm at selected sites within the Tempus network. This algorithm was used during routine xR (whole transcriptome RNA) tests to identify patients who may benefit from additional confirmatory IHC HER2 testing. -
ArticlesQ&A: A deep dive into the science and significance of Tempus’ Immune Profile Score (IPS)
In this Q&A, Dr. Michelle Ting-Lin, Medical Director of Clinical Development at Tempus, provides insights into the science behind the Immune Profile Score (IPS), a novel biomarker designed to enhance the identification of patients who may benefit from immune checkpoint inhibitor (ICI) therapies. -
ArticlesQ&A: AI algorithms in cardiology: From research to clinical practice
In a recent webinar hosted by Tempus, experts gathered to discuss the integration of AI algorithms into cardiology, focusing on the journey from research to practical application in patient care. -
Case StudiesNavigating complex cell therapy trials with Compass CRO
Learn how Compass provided CRO services for a biotech’s first-in-human, dose-escalation, and expansion basket trial targeting advanced solid tumors. -
ArticlesQ&A: Harnessing AI with multimodal data to transform drug development
Dr. Kate Sasser, PhD, Chief Scientific Officer at Tempus, discusses how Tempus layers ML and AI on multimodal data to drive insights and propel various stages of drug discovery and development. -
Webinars
Precision pathways: Insights & strategies to navigate regulatory requirements for oncology diagnostics
Watch as we explore the evolving regulatory landscape of diagnostics in oncology. Gain insights into new regulatory requirements, submission pathways, and emerging trends. Learn from industry experts about strategic approaches to FDA requirements to help inform your diagnostic development and precision medicine pipelines. -
Case StudiesRevolutionizing drug screening with Tempus AI’s advanced imaging capabilities
Learn how Tempus AI's noninvasive imaging techniques allow for the continuous study of the same organoids across various assays, preserving their viability for longitudinal analysis and multiplexed testing. -
WebinarsShaping drug development with tumor organoids and RWD
Explore how Tempus addresses drug development challenges through its extensive 3D patient-derived organoid (PDO) biorepository and real-world data (RWD) platform. -
Case StudiesHarnessing AI and TIME to increase clinical trial enrollment
Cleveland Clinic studies the impact of AI to meaningfully streamline and increase trial access and enrollment. -
WebinarsAI algorithms in cardiology: Navigating the path from research to practice
Unlock the Future of Cardiology with AI. Join Tempus for an in-depth webinar exploring the transformative power of AI algorithms in cardiology research and clinical practice. -
Webinars
Enhancing psychiatric care with pharmacogenomics (PGx)
Tune in as clinicians discuss PGx, and its application in psychiatric medication management. Our expert speakers will guide you through patient case studies and real-world PGx reports, and highlight the role of pharmacogenomics to inform personalized treatment decisions in mental health. -
ArticlesQ&A: Advancing immunotherapy biomarker identification with Immune Profile Score (IPS)
Jason Blue-Smith, VP & GM of Algos at Tempus, discusses the challenges in immunotherapy biomarker identification and how Tempus’ Immune Profile Score (IPS) offers solutions to these problems. -
Webinars
Scientific breakthroughs across the cancer continuum: Research from the 2024 ASCO® Annual Meeting
Join experts as they discuss innovative approaches to patient management in cancer care. Learn about new data from the 2024 ASCO® Annual Meeting, including Tempus' new MRD and monitoring portfolio, major lung cancer trial discoveries, and advancements in outcomes for advanced breast cancer. -
ArticlesQ&A: The evolving role of antibody-drug conjugates in oncology
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons.
